Where the Purple Saxifrage Blooms: My Arctic Shoreline Encounters with PH
While every PHighter’s journey is unique, certain patients’ stories stand out as particularly exceptional. Living in Kugluktuk, Nunavut, an Inuit community of 1,500 bordering the Arctic Ocean, Millie Kuliktana has overcome many challenges that accompany life with PH in one of Canada’s most northern communities.
Cancer Marker NEDD9 Could Be a Therapeutic Target for PAH, Study Suggests
A cancer marker called NEDD9 is a critical mediator of pulmonary arterial hypertension (PAH) and could be a therapeutic target, according to new research. The study, “NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension,” was published in the journal Science Translational Medicine. Fibrosis (scarring) is an important source of damage in lung arteries of patients with PAH, resulting in an increased effort …
Age-Obesity Interaction in Pulmonary Arterial Hypertension
No correlation between obesity and mortality in individuals with pulmonary arterial hypertension (PAH) was observed; however, the interaction of age and obesity with respect to survival showed an increased risk for mortality in young adults who were morbidly obese, according to a study published in CHEST. Data were drawn from the French Pulmonary Hypertension Registry, and a cohort of 1255 incident participants were characterized with idiopath…
PAH in Systemic Sclerosis Increases Risk for Early Mortality
In patients with systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH), approximately 50% of deaths are PAH related, according to an article published in CHEST. Risk factors for mortality include male sex, diffuse disease, systolic pulmonary artery pressure (PAP) on echocardiogram, mean PAP on right heart catheterization (RHC), 6-minute walk distance (6MWD), and diffusing capacity for carbon monoxide (DLCO).
85 per cent of Canadians now have publicly funded access to a potentially life-extending treatment for patients with rare lung disease
Vancouver, BC/Hamilton, ON (Tuesday, June 12, 2018) – The Pulmonary Hypertension Association of Canada (PHA Canada) and Scleroderma Canada join together in praising the Alberta, Saskatchewan, Manitoba, Ontario and Newfoundland and Labrador governments for following Quebec’s lead by providing public funding for Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH). This action stems from the conclusion of pricing negotiati…
Canada Trails US in Patient Access to Rare Disease Therapies, CORD President Says
Canada’s healthcare system is excellent for people with common ailments like diabetes or high blood pressure, but it’s “basically failing the nearly three million Canadians with rare diseases.” So says Durhane Wong-Rieger, president and CEO of the Canadian Organization for Rare Disorders (CORD), a Toronto-based network representing 102 patient advocacy groups.
Scleroderma and PAH
Scleroderma is a progressive chronic disease that causes hardening and thickening of the skin and internal organs. Scleroderma is an autoimmune disease, meaning that the body’s immune system attacks its own tissues, resulting in inflammation and damage. In scleroderma, the body produces an excess amount of collagen (a type of protein), which can lead to scarring of the skin, tissues under the skin (including muscles and bones), and internal organ…
Eastern Regional Symposium: A place to learn, connect & be inspired
Last year we welcomed over 220 members of the pulmonary hypertension (PH) community to our first Eastern Regional Symposium, held in Toronto, Ontario on October 13th-14th. With attendees from across Eastern Canada, we had the pleasure of reuniting with old PHriends, while also meeting many new members of the Canadian PHamily. We kicked things off on Friday night with a casual welcome reception, where a scavenger hunt helped us break the ice and g…
Direct Oral Anticoagulants Show Promising Results for CTEPH Treatment in Small Study
Direct oral anticoagulants — a type of blood thinner medication — are a safe and effective treatment for chronic thromboembolic pulmonary hypertension (CTEPH), according to a small study. The study, “Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension,” was published in the journal Clinics. CTEPH, a rare form of pulmonary hypertension, is caused by blood clots that travel to the lungs and obstruct the lungs’ …
How New Drugs Go from Being Developed to Being Administered to Patients
Innovative research is being done around the world to develop new therapies to better manage PH. However, it can take years before patients gain access to a newly developed drug. The journey from the research bench—where ideas for new drugs originate and are initially tested—to the patient’s bedside—where treatments reach those in need—is long and complex. In Canada, all new treatments go through a rigorous approval process to ensure that availab…
« Previous123456...42Next »
Recent News


Get the latest on PH treatments, community events and more when you subscribe to our newsletter